The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Updates on the use of ropeginterferon in the treatment of MPNs
Ghaith Abu-Zeinah, MD, Weill Cornell Medicine, New York, NY, provides a comprehensive overview of his talk discussing updates on ropeginterferon for the treatment of myeloproliferative neoplasms (MPNs). Dr Abu-Zeinah outlines data from the PROUD-PV (NCT01949805), CONTINUATION-PV (NCT02218047), and Low-PV (NCT03003325) trials and discusses the potential for an accelerated dosing schedule for this agent, which is being studied in the Phase IIIb ECLIPSE PV trial (NCT05481151). Following this, Dr Abu-Zeinah highlights the findings of a retrospective analysis comparing the safety and efficacy of ropeginterferon to the older, more established peginterferon in patients with polycythemia vera (PV). Finally, he touches upon trials investigating ropeginterferon in essential thrombocythemia (ET) and primary myelofibrosis (PMF). This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
